Market Research Logo

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2015’, provides an overview of the Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Chronic Lymphocytic Leukemia (CLL) Overview
Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
Drug Profiles
Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2015
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amorfix Life Sciences Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprogen, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioInvent International AB, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Conkwest, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by CTI BioPharma Corp., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline Plc, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hospira, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MediGene AG, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Molecular Templates Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Neopharm Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Nimbus Therapeutics, LLC, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by SpectraMab GmbH, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys S.A., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by ViDAC Pharma Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H1 2015
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H1 2015
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2015
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2015
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report